Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

被引：0
|
作者：
M. R. McClung
P. D. Miller
J. P. Brown
J. Zanchetta
M. A. Bolognese
C. L. Benhamou
A. Balske
D. E. Burgio
J. Sarley
L. K. McCullough
R. R. Recker
机构：
[1] Oregon Osteoporosis Center,
[2] Colorado Center for Bone Research,undefined
[3] Groupe de recherche en rhumatologie et maladies osseuses,undefined
[4] University of El Salvador,undefined
[5] Metabolic Research Institute,undefined
[6] Bethesda Health Research,undefined
[7] Institut de Prévention et de Recherche sur l’Ostéoporose,undefined
[8] Abbott Laboratories,undefined
[9] Procter and Gamble Pharmaceuticals,undefined
[10] The Procter and Gamble Company,undefined
[11] Warner Chilcott Pharmaceuticals Inc,undefined
[12] Ben Venue Laboratories,undefined
[13] ICON Clinical Research,undefined
[14] Creighton University,undefined
[15] Osteoporosis Research Center,undefined
来源：
Osteoporosis International | 2012年 / 23卷
关键词：
Bone mineral density; Delayed-release; Enteric-coated; Fracture risk; Osteoporosis; Risedronate; Weekly;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：267 / 276
页数：9
相关论文
共 50 条
  • [21] A 26-WEEK STUDY OF EFFICACY AND SAFETY OF DELAYED-RELEASE PREDNISONE IN NEWLY DIAGNOSED CASES OF GIANT CELL ARTERITIS: AN INTERIM ANALYSIS
    Raine, Charles
    Maw, Win
    Williams, Mark
    Gayford, Dawn
    Mapplebeck, Sarah
    Mackerness, Craig
    Dasgupta, Bhaskar
    RHEUMATOLOGY, 2014, 53 : 7 - 8
  • [22] Efficacy and safety of delayed-release oral mesalamine at 4.8g/D (800mg tablet) in the treatment of moderately active ulcerative colitis: Results of the Ascend III study
    Sandborn, William J.
    Regula, Jaroslaw
    Feagan, Brian
    Belousova, Elena A.
    Jojic, Njegica V.
    Lukas, Milan
    Yacyshyn, Bruce R.
    Krzeski, Piotr
    Yeh, Chyon-Hwa
    Hanauer, Stephen B.
    GASTROENTEROLOGY, 2008, 134 (04) : A99 - A99
  • [23] Increased Efficacy of Delayed-Release Mesalamine 4.8g/D (800mg Tablet) in Patients Previously Diagnosed with Ulcerative Colitis (UC)
    Sandborn, William J.
    Ramsey, David
    Vandergeest, Stefan
    GASTROENTEROLOGY, 2009, 136 (05) : A520 - A520
  • [24] Once-Daily Dosing of Delayed-Release Oral Mesalamine (400-mg Tablet) Is as Effective as Twice-Daily Dosing for Maintenance of Remission of Ulcerative Colitis
    Sandborn, William J.
    Korzenik, Joshua
    Lashner, Bret
    Leighton, Jonathan A.
    Mahadevan, Uma
    Marion, James F.
    Safdi, Michael
    Sninsky, Charles A.
    Patel, Raman M.
    Friedenberg, Keith A.
    Dunnmon, Preston
    Ramsey, David
    Kane, Sunanda
    GASTROENTEROLOGY, 2010, 138 (04) : 1286 - U117
  • [25] Once Daily Dosing of Delayed-Release Oral Mesalamine (400 mg Tablet) is as Effective as Twice Daily Dosing for Maintenance of Remission of Ulcerative Colitis: Results of the QDIEM Study
    Sandborn, William
    Kane, Sunanda
    Korzenik, Joshua
    Lashner, Bret
    Leighton, Jonathan
    Mahadevan, Uma
    Marion, James
    Safdi, Michael
    Sninsky, Charles
    Ramsey, David
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S438 - S439
  • [26] A 26-WEEK STUDY OF EFFICACY AND SAFETY OF DELAYED-RELEASE PREDNISONE IN NEWLY-DIAGNOSED CASES OF GIANT CELL ARTERITIS: AN INTERIM ANALYSIS
    Raine, C.
    Maw, W. W.
    Williams, M.
    Gayford, D.
    Mapplebeck, S.
    Borg, F. A.
    Mackerness, C.
    Hirst, D.
    Dasgupta, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 551 - 551
  • [27] Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study
    Hyun Lim
    Jong Kyu Park
    Hyunsoo Chung
    Si Hyung Lee
    Jae Myung Park
    Jung Ho Park
    Gwang Ha Kim
    Sung Kwan Shin
    Su Jin Hong
    Kwang Jae Lee
    Moo In Park
    Hye-Kyung Jung
    Hyun-Soo Kim
    Jae Kyu Sung
    Seong Woo Jeon
    Suck Chei Choi
    Jeong Seop Moon
    Nayoung Kim
    Jong-Jae Park
    Sung Hee Hong
    Na Young Kim
    Hwoon-Yong Jung
    BMC Gastroenterology, 23
  • [28] Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium
    Horne, RL
    Cunanan, C
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (02) : 176 - 181
  • [29] Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study
    Lim, Hyun
    Park, Jong Kyu
    Chung, Hyunsoo
    Lee, Si Hyung
    Park, Jae Myung
    Park, Jung Ho
    Kim, Gwang Ha
    Shin, Sung Kwan
    Hong, Su Jin
    Lee, Kwang Jae
    Park, Moo In
    Jung, Hye-Kyung
    Kim, Hyun-Soo
    Sung, Jae Kyu
    Jeon, Seong Woo
    Choi, Suck Chei
    Moon, Jeong Seop
    Kim, Nayoung
    Park, Jong-Jae
    Hong, Sung Hee
    Kim, Na Young
    Jung, Hwoon-Yong
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [30] Efficacy and Safety of Pancrelipase Delayed-Release Capsules in Patients with Pancreatic Insufficiency Due to Cystic Fibrosis
    Trapnell, Bruce
    Maguiness, Karen M.
    Graff, Gavin R.
    Boyd, David
    Caras, Steven D.
    Beckmann, Katrin
    Bennett, Djenane
    GASTROENTEROLOGY, 2009, 136 (05) : A322 - A322
12345